2.21

0.45% -0.01

Prokidney Corp (PROK)

Overview News Price History Option Chain Financials Discussions Forecast

Prokidney Corp stock is traded at $2.21, with a volume of 815.44K. It is down -0.45% in the last 24 hours and down -17.54% over the past month. ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Previous Close:

$2.22

Open:

$2.22

24h Volume:

815.44K

Relative Volume:

0.42

Market Cap:

$312.82M

Revenue:

Net Income/Loss:

$-35.47M

P/E Ratio:

-3.8772

EPS:

-0.57

Net Cash Flow:

$-124.27M

1W Performance:

-5.56%

1M Performance:

-17.54%

6M Performance:

+146.65%

1Y Performance:

+17.55%

1-Day Range:

$2.20

$2.28

1-Week Range:

$2.09

$2.445

52-Week Range:

$0.4603

$7.13

Prokidney Corp Stock (PROK) Company Profile

Name

Prokidney Corp

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

336-999-7028

Address

2000 FRONTIS PLAZA BLVD., WINSTON-SALEM

Employee

204

Twitter

Next Earnings Date

2024-12-09

Latest SEC Filings

PROK's Discussions on Twitter

Compare PROK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PROK Prokidney Corp	2.21	314.23M	0	-35.47M	-124.27M	-0.57
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-30-25	Downgrade	BofA Securities	Neutral → Underperform
Sep-30-24	Initiated	JP Morgan	Neutral
Sep-10-24	Initiated	Guggenheim	Buy
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight
Jan-02-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-23	Initiated	BTIG Research	Buy
Dec-21-22	Initiated	Jefferies	Buy
Nov-10-22	Initiated	Morgan Stanley	Equal-Weight
Oct-18-22	Initiated	UBS	Buy
Oct-14-22	Initiated	Citigroup	Buy
Sep-23-22	Initiated	BofA Securities	Buy
Sep-02-22	Initiated	Evercore ISI	Outperform

View All

Prokidney Corp Stock (PROK) Latest News

Dec 12, 2025

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts - MarketBeat

Dec 12, 2025

Dec 06, 2025

ProKidney (NASDAQ:PROK) Trading Down 6.8%What's Next? - MarketBeat

Dec 06, 2025

Dec 05, 2025

Why ProKidney Corp. stock remains resilientJuly 2025 Earnings & Real-Time Volume Analysis - Newser

Dec 05, 2025

Dec 02, 2025

Promising Penny Stocks To Watch In December 2025 - simplywall.st

Dec 02, 2025

Nov 29, 2025

ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN

Nov 29, 2025

Nov 28, 2025

What drives ProKidney Corp stock priceCurrency Fluctuation Impact & Rapid Capital Trading Tips - earlytimes.in

Nov 28, 2025

Nov 24, 2025

ProKidney site sells Greensboro site for $6.5M less than it paid for property - The Business Journals

Nov 24, 2025

Nov 23, 2025

While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownership - Yahoo Finance

Nov 23, 2025

Nov 21, 2025